Gus Gazzard

About Gus Gazzard

Gus Gazzard, our leading 2026 Power Lister, says: “My interests are increasingly focussed on improving how we might conduct randomized controlled trials in ophthalmology – I’ve been fascinated by RCTs since I entered medicine, fed on semi-mythical stories of lime-eating sailors and early antibiotic studies! Our resources to test and compare treatments adequately are already lagging behind the pace at which we generate new possibilities for therapy, which creates many risks for patients, and that gap will  only widen. It is that gap which is my motivation.” 

“Working with many others I’ve been looking into better RCT outcome measures with sensitive but robust visual field analyses, the applications of WIN ratios for composite trial outcomes, fragility indices to measure robustness of trial results, and the exciting possibilities offered by Registry RCTs,  in addition of course to the studies and development of treatments themselves, particularly drop-independent therapies.”

“Without RCTs, which preserve the glorious power of randomization to give us robust answers, we fall prey to bias, selective reporting and ulterior motives.”

“I hope that the impact of this work may have been (and will be) to encourage colleagues to look ever more critically at the information we receive, but more importantly to improve trial design within our speciality and ultimately to make it easier to answer those questions to which our patients need the answers.”